We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Editorial: important insights into prescribing practices and training needs of gastroenterologists regarding use of central neuromodulators in IBS.
- Authors
Akbani, Umair; Vasant, Dipesh H.
- Abstract
Irritable bowel syndrome (IBS) is a painful disorder of gut-brain interaction (DGBI) with a substantial worldwide prevalence.1 Despite being one of the most common conditions seen by gastroenterologists, IBS is often considered a difficult condition to manage, and is unfortunately often subject to stigmatisation.2 In recent years, there has been increasing recognition of the multifactorial nature of the condition and the importance of holistic treatment within a biopsychosocial framework.3 Based on modern understanding of the gut-brain axis and DGBI such as IBS, there is compelling evidence for the use of gut-brain therapies such as centrally acting neuromodulators4 and IBS-specific psychological approaches, reflected in recently updated IBS guidelines.5,6 Central neuromodulators have a particularly important role in targeting visceral hypersensitivity or centrally mediated gastrointestinal pain, where opioids can be detrimental, and should be avoided.7 In this context, Nulsen et al. conducted a survey on the use of central neuromodulators by gastroenterologists in North America, and identified factors which underpinned clinicians' prescribing habits.8 The survey, which is the largest of its kind, included responses from 525 gastroenterologists. 8 Nulsen B, LeBrett W, Drossman DA, Chang L. A survey of gastroenterologists in the United States on the use of central neuromodulators for treating irritable bowel syndrome.
- Publication
Alimentary Pharmacology & Therapeutics, 2021, Vol 54, Issue 3, p339
- ISSN
0269-2813
- Publication type
Academic Journal
- DOI
10.1111/apt.16495